These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22621454)

  • 1. Lessons from Lumiracoxib: are cyclooxygenase-2 inhibitors less hepatotoxic than non-selective non-steroidal anti-inflammatory drugs?
    Chitturi S; Farrell GC
    J Gastroenterol Hepatol; 2012 Jun; 27(6):993-4. PubMed ID: 22621454
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lumiracoxib taken off the market in Australia. What does that mean for our patients? (interview by Dr. Judith Neumaier)].
    Brune K
    MMW Fortschr Med; 2007 Sep; 149(39):6. PubMed ID: 17987737
    [No Abstract]   [Full Text] [Related]  

  • 3. Lumiracoxib-induced cholestatic liver injury.
    Fok KC; Bell CJ; Read RB; Eckstein RP; Jones BE
    Intern Med J; 2013 Jun; 43(6):731-2. PubMed ID: 23745998
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe acute liver injury associated with lumiracoxib.
    Pillans PI; Ghiculescu RA; Lampe G; Wilson R; Wong R; Macdonald GA
    J Gastroenterol Hepatol; 2012 Jun; 27(6):1102-5. PubMed ID: 22142375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability of lumiracoxib in patients with analgesic intolerance.
    Celikel S; Isik SR; Karakaya G; Kalyoncu AF
    J Investig Allergol Clin Immunol; 2008; 18(4):318-9. PubMed ID: 18714545
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
    Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
    Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of takotsubo cardiomyopathy precipitated by lumiracoxib, a selective COX-2 inhibitor.
    Ker J; Van Wyk CJ
    Cardiovasc J Afr; 2007; 18(6):383-4. PubMed ID: 18092115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
    Hawkey CJ; Weinstein WM; Smalley W; Gitton X; Sallstig P; Stricker K; Krammer G; Mellein B; Richard D; Matchaba P
    Gastroenterology; 2007 Jul; 133(1):57-64. PubMed ID: 17631131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lumiracoxib--Prexigem].
    Duh D; Vandevijver A
    J Pharm Belg; 2007; 62(3):95-6. PubMed ID: 17955960
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
    MacDonald TM; Reginster JY; Littlejohn TW; Richard D; Lheritier K; Krammer G; Rebuli R
    J Hypertens; 2008 Aug; 26(8):1695-702. PubMed ID: 18622250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?
    Hinz B; Renner B; Cheremina O; Besz D; Zolk O; Brune K
    Ann Rheum Dis; 2009 Feb; 68(2):289-91. PubMed ID: 19139209
    [No Abstract]   [Full Text] [Related]  

  • 12. [Toxic hepatitis caused by aceclofenac].
    Fernández-Avala Novo M; Penado Nadela S; Nan Nan DN; González Macías J
    Rev Clin Esp; 2001 Oct; 201(10):616-7. PubMed ID: 11817238
    [No Abstract]   [Full Text] [Related]  

  • 13. [Aceclofenac-induced hepatitis].
    Hernández Beriain J; Segura García C
    Rev Esp Enferm Dig; 1995 Jul; 87(7):550-1. PubMed ID: 7662428
    [No Abstract]   [Full Text] [Related]  

  • 14. [NSAID-induced hepatotoxicity: aceclofenac and diclofenac].
    Zaragoza Marcet A; Alfonso Moreno V; Roig Catalá E
    Rev Esp Enferm Dig; 1995 Jun; 87(6):472-5. PubMed ID: 7612373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatic toxicity caused by aceclofenac].
    Prieto de Paula JM; Romero Castro R; Villamandos Nicás YV
    Gastroenterol Hepatol; 1997 Mar; 20(3):165. PubMed ID: 9162542
    [No Abstract]   [Full Text] [Related]  

  • 16. [Toxic hepatitis caused by aceclofenac].
    Pérez Moreno JM; Puertas Montenegro M; Fernández Ruiz A; Fernández González MA
    Rev Esp Enferm Dig; 1996 Nov; 88(11):815-6. PubMed ID: 9004792
    [No Abstract]   [Full Text] [Related]  

  • 17. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R; Berry C; Du Z; Dawson J; Fox A; Fujimoto RA; Haston W; Kimble EF; Koehler J; Peppard J; Quadros E; Quintavalla J; Toscano K; Urban L; van Duzer J; Zhang X; Zhou S; Marshall PJ
    Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P; Gitton X; Krammer G; Ehrsam E; Sloan VS; Olson M; Mellein B; Hoexter G; Orloff J; Garaud JJ
    Clin Ther; 2005 Aug; 27(8):1196-214. PubMed ID: 16199245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind study comparing lumiracoxib with naproxen for acute musculoskeletal pain.
    Kyle C; Zachariah J; Kinch H; Ellis G; Andrews C; Adekunle F
    Int J Clin Pract; 2008 Nov; 62(11):1684-92. PubMed ID: 19143855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment--findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial.
    Hawkey CJ; Weinstein WM; Stricker K; Murphy V; Richard D; Krammer G; Rebuli R
    Aliment Pharmacol Ther; 2008 May; 27(9):838-45. PubMed ID: 18221410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.